GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Immunovia AB (OSTO:IMMNOV) » Definitions » EV-to-Revenue

Immunovia AB (OSTO:IMMNOV) EV-to-Revenue : 21.97 (As of May. 14, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Immunovia AB EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Immunovia AB's enterprise value is kr26.63 Mil. Immunovia AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was kr1.21 Mil. Therefore, Immunovia AB's EV-to-Revenue for today is 21.97.

The historical rank and industry rank for Immunovia AB's EV-to-Revenue or its related term are showing as below:

OSTO:IMMNOV' s EV-to-Revenue Range Over the Past 10 Years
Min: -48.08   Med: 6884.58   Max: 23938.02
Current: 21.98

During the past 11 years, the highest EV-to-Revenue of Immunovia AB was 23938.02. The lowest was -48.08. And the median was 6884.58.

OSTO:IMMNOV's EV-to-Revenue is ranked worse than
91.07% of 224 companies
in the Medical Diagnostics & Research industry
Industry Median: 3.21 vs OSTO:IMMNOV: 21.98

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-14), Immunovia AB's stock price is kr1.524. Immunovia AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was kr0.03. Therefore, Immunovia AB's PS Ratio for today is 56.44.


Immunovia AB EV-to-Revenue Historical Data

The historical data trend for Immunovia AB's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunovia AB EV-to-Revenue Chart

Immunovia AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9,282.91 6,249.61 1,709.98 460.04 4.92

Immunovia AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 86.75 -22.79 -23.89 4.92 16.15

Competitive Comparison of Immunovia AB's EV-to-Revenue

For the Diagnostics & Research subindustry, Immunovia AB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunovia AB's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Immunovia AB's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Immunovia AB's EV-to-Revenue falls into.



Immunovia AB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Immunovia AB's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=26.633/1.212
=21.97

Immunovia AB's current Enterprise Value is kr26.63 Mil.
Immunovia AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immunovia AB  (OSTO:IMMNOV) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Immunovia AB's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1.524/0.027
=56.44

Immunovia AB's share price for today is kr1.524.
Immunovia AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.03.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immunovia AB EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Immunovia AB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunovia AB (OSTO:IMMNOV) Business Description

Traded in Other Exchanges
Address
Medicon Village, Scheelevagen 8, Lund, SWE, 223 63
Immunovia AB molecular diagnostic company. It develops and commercializes diagnostic tools for complex forms of cancer and autoimmune diseases. Its technology platform IMMray (TM), is based on antibody microarray analysis. The group's intangible and tangible assets are in Sweden, in the United States and in Germany.

Immunovia AB (OSTO:IMMNOV) Headlines

No Headlines